<DOC>
	<DOCNO>NCT01131169</DOCNO>
	<brief_summary>The patient offer stem cell transplant . Stem cell early blood cell . They yet mature become red white blood cell platelet . They already receive standard treatment chemotherapy autologous stem cell transplant . An autologous stem cell transplant patient receive infusion cell . Thi give patient well chance cure disease , protocol include infusion stem cell blood ( bone marrow ) another person . This call allogeneic stem cell transplant . The stem cell begin grow bone marrow produce new blood cell . Allogeneic stem cell transplant cause condition call graft-versus-host disease GVHD . In GVHD , kind white blood cell donor ( graft ) begin attack body ( host ) . That blood cell call T-cell . It cell normally help protects thing like bacteria virus . In case , donor 's T-cells see body foreign way would see bacteria foreign . GVHD fatal . In order low chance patient get GVHD protocol treatment remove T-cells donor 's cell . This call T-cell depletion . The T cell remove system call `` Clinimacs '' . This method still evaluate clinical trial approve Federal Drug Administration ( FDA ) time . Before transplant , physician treat bone marrow get rid cancer . The physician us three chemotherapy drug plus ATG . The chemotherapy drug ( Busulfan , Melphalan Fludarabine ) kill cancer . ATG get rid patient T cell survive chemotherapy . This ensure donor stem cell reject . The patient also receive additional white blood cell call lymphocyte donor . This call donor lymphocyte infusion DLI . These additional infusion help cause graft-versus-myeloma effect help donor stem cell grow .</brief_summary>
	<brief_title>Busulfan , Melphalan , Fludarabine T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed Post Transplantation Donor Lymphocyte Infusions</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patient must multiple myeloma either relapse high risk cytogenetics . Patients relapse multiple myeloma follow autologous stem cell transplantation must achieve least partial response follow additional chemotherapy ( cohort 1 ) : Patients eligible relapse occur complex/highrisk cytogenetics occur normal cytogenetics within 15 month follow autologous transplant . Patients high risk cytogenetics diagnosis must achieve least good partial response follow autologous stem cell transplantation ( cohort 2 ) : Patients must complex karyotype , 1q25 , del17p , t4 ; 14 and/or t14 ; 16 FISH and/or del13 karyotyping . DONOR : Patients must healthy HLA match mismatch relate unrelated donor willing receive GCSF injection undergo apheresis PBSC collection , undergo marrow harvest procedure . 1 . HLAmatched related unrelated donor Patients HLAmatched relate unrelated donor eligible entry protocol . This include healthy donor genotypically match A , B , C , DRB1 DQB1 locus , locus , test DNA analysis . 2 . HLA mismatch related unrelated donor Patients HLAmatched donor relate unrelated donor one antigen one allele mismatch HLA A , B , C , DRB1 DQB1 locus ; two mismatch , HLADQB1 one locus , eligible entry protocol . The following inclusion criterion also require : Patients ≥ 21 , &lt; 73 year old . Patients may either gender ethnic background . Patients must Karnofsky ( adult ) Performance Status ≥ 70 % Patients must adequate organ function measure : Cardiac : asymptomatic symptomatic LVEF rest must ≥ 50 % must improve exercise . Hepatic : &lt; 3x ULN ALT ≤ 1.5 total serum bilirubin , unless congenital benign hyperbilirubinemia . Renal : serum creatinine &lt; 1.2 mg/dl serum creatinine outside normal range , CrCl &gt; 40 ml/min ( measure calculated/estimated ) dose adjustment Fludarabine &lt; 70ml/min . Pulmonary : asymptomatic symptomatic , DLCO &gt; 50 % predict ( correct hemoglobin ) Each patient must willing participate research subject must sign informed consent form . Patients achieve &lt; Partial Response follow precede chemotherapy ( cohort 1 ) &lt; Very Good Partial Response follow autologous stem cell transplantation ( cohort 2 ) . Patients Plasma Cell Leukemia . Female patient pregnant breastfeed Active viral , bacterial fungal infection Patient seropositive HIVI/II ; HTLV I/II Patients undergone prior allogeneic hematopoietic stem cell transplantation . Patients previous malignancy remission . Patients know hypersensitivity mouse protein ( murine antibody ISOLEX ) receive SBAE bone marrow , chicken egg product .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>T-Cell</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>10-051</keyword>
</DOC>